Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $15.84 and last traded at $15.79, with a volume of 208,923 shares trading hands. The stock had previously closed at $15.41.

A number of equities research analysts recently issued reports on LXRX shares. Wedbush lifted their target price on Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, May 31st. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Cowen and Company reissued a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, May 4th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $16.00 target price on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $18.50.

The company’s market capitalization is $1.64 billion. The firm’s 50-day moving average price is $14.39 and its 200-day moving average price is $12.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.04. During the same quarter in the previous year, the business earned ($0.04) EPS. The business earned $12.50 million during the quarter, compared to analysts’ expectations of $11.11 million. The company’s revenue was up 594.4% on a year-over-year basis. Analysts predict that Lexicon Pharmaceuticals Inc. will post ($1.55) EPS for the current year.

In related news, VP James F. Tessmer sold 6,000 shares of the company’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $78,000.00. Following the sale, the vice president now owns 21,946 shares in the company, valued at approximately $285,298. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Other large investors have made changes to their positions in the company. California State Teachers Retirement System raised its stake in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,372 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 6,390 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 77,446 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 125,083 shares during the last quarter.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.